Yahoo Finance 
Short Bowel Syndrome Market Report 2021-2031: Visiongain Research Inc.
Visiongain has published a new report on Short Bowel Syndrome Market Report 2021-2031: Forecasts By Treatment (Nutritional Support, Medications, Surgery, Intestinal Transplant, and Others), By Type (Small Intestine, and Large Intestine), By Patient Demographics (Adults, Geriatric, Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS, COVID-19 Recovery Scenarios.
COVID-19 Impact on Short Bowel Syndrome
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Short Bowel Syndrome. Different recovery scenarios are also included in the report for all the segments and regions/nation.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/short-bowel-syndrome-market-2021/#download_sampe_div
Market Drivers
Increasing Prevalence of short bowel syndrome around the World
The burden of short bowel syndrome is increasing very rapidly around the world however it is a rare disease, and it is expected to continuously rise over the forecast period. Short bowel syndrome occurs due to surgery for removal of a portion of the small intestine, cancer and damage to the intestines caused by cancer treatment, Crohn’s disease, and among others. The increasing prevalence of short bowel syndrome is creating a huge demand for the short bowel syndrome therapeutics for the treatment of short bowel syndrome. Due to which increasing prevalence of short bowel syndrome around the world is working as a driver for the pain management therapeutics market.
Increasing geriatric population around the world
An increasing in geriatric population is suffering from short bowel syndrome. All regions are facing a huge increase in the number of geriatric populations. For instance: According to the United Nations, Department of Economic and Social Affairs, the Population Division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Geriatric population is more prone to short bowel syndrome. Rapid increase in the number of the geriatric population around the globe is also increasing demand for short bowel syndrome around the world. Due to which an increasing geriatric population around the world is working as a driver for the short bowel syndrome.
Market Opportunities
Increasing Focus on Advance Therapeutics
Researchers and pharmaceutical manufacturers from all over the world are increasing their focus on research and development for advance therapeutics for the treatment of short bowel syndrome and are taking required steps to create or advance therapeutics for short bowel syndrome treatment. Researcher and pharmaceutical manufacture in developing nations are undergoing regress research and development from the last few years. Increasing focus on advanced therapeutics for short bowel syndrome treatment is expected to increase the number of advanced therapeutics for short bowel syndrome treatment which is expected to create new opportunities for short bowel syndrome.
Get Detailed TOC @ https://www.visiongain.com/report/short-bowel-syndrome-market-2021/#download_sampe_div
How the Short Bowel Syndrome Market report helps you
In summary, our 320+ page report provides you with the following knowledge:
Revenue forecasts to 2031 for Short Bowel Syndrome Market, with forecasts for Get our report today Short Bowel Syndrome Market Forecast 2021-2031: By Treatment, Type, Patient Demographics, By End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Short Bowel Syndrome market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Short Bowel Syndrome Market.
Competitive Landscape
Top companies (Shire plc (Takeda Pharmaceutical Company Limited), Zealand Pharma A/S, Sancilio & Company, Inc.) constitute more than XX% share of the global Short Bowel Syndrome. Other companies profiled in the report include: OxThera, Nutrinia Ltd., Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc. (Pfizer Inc.), Merck KGaA, Naia Pharmaceuticals, Inc. Some of the key developments are listed below:
In 2019, Takeda Pharmaceuticals, U.S.A., Inc. received U.S. Food and Drug Administration (FDA) approval for GATTEX (teduglutide). GATTEX (teduglutide) is specially designed for the treatment of pediatric patients 1 year of age and older with short bowel syndrome (SBS). The approval will help the company to expand its short bowel syndrome portfolio and widened revenue generation from market focused product portfolio.
In 2020, VectivBio has received $35 million in financing from OrbiMed, Tekla Healthcare Investors, Versant Ventures, Novo Holdings, BPI France, Inserm Transfert Initiative and Cowen Healthcare Investments. The company is a clinical-stage biotechnology company and developing apraglutide (under Phase 2 trials) for treatment of short bowel syndrome. The new financing will help the company to speed up development of the market focus product.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Short Bowel Syndrome Market and leading companies. You will find data, trends, and predictions.
Find more Visiongain's research reports of Therapeutic Drugs Sector click on the following links:
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.
